VX-765: Selective Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a pro-drug that selectively inhibits caspase-1, reducing the release of IL-1β and IL-18 with minimal off-target effects (APExBIO product page). Its active metabolite, VRT-043198, blocks caspase-1-driven pyroptosis in macrophages and T cells (Johnson et al., 2020). VX-765 has shown anti-inflammatory efficacy in preclinical models of arthritis and skin inflammation. The compound demonstrates high solubility in DMSO (≥313 mg/mL) and is insoluble in water, requiring careful formulation. As a benchmark tool, VX-765 supports targeted investigation of inflammasome signaling, with defined limits regarding cytokine specificity and cell-type responses.

Biological Rationale

Inflammasomes are multiprotein complexes that detect intracellular pathogens or danger signals. Their canonical signaling pathway involves a pattern recognition receptor (PRR) recruiting pro-caspase-1 via the adaptor ASC (Johnson et al., 2020). Upon activation, caspase-1 cleaves pro-interleukin-1β (pro-IL-1β) and pro-IL-18, generating their bioactive forms. This cleavage also triggers gasdermin D pore formation, releasing cytokines and inducing pyroptosis—a rapid, lytic form of programmed cell death, predominantly in macrophages and monocytes. Precise modulation of caspase-1 is vital for dissecting inflammatory signaling and understanding autoimmune, infectious, and neurodegenerative disease mechanisms. Orally bioavailable, selective caspase-1 inhibitors like VX-765 allow for controlled, reproducible inhibition of this axis in animal and cell models (see prior synthesis—this article provides updated specificity data and workup details).

Mechanism of Action of VX-765

VX-765 is an orally absorbed pro-drug. In vivo, it is converted by esterases to the active compound VRT-043198 (APExBIO). VRT-043198 is a potent, selective inhibitor of caspase-1 (ICE, interleukin-1 converting enzyme). Caspase-1 belongs to the ICE/caspase-1 sub-family, mediating the final cleavage of IL-1β and IL-18 precursors. VX-765 does not inhibit other caspases or proteases at tested concentrations (10–100 µM in buffered pH 7.5 media). Blockade of caspase-1 by VX-765 results in reduced IL-1β and IL-18 secretion, without affecting TNFα, IL-6, IL-8, or IL-α release. Pyroptosis, driven by gasdermin D activation, is also inhibited in responsive cell types such as macrophages and select T cells (Johnson et al., 2020). This selectivity enables researchers to attribute observed effects to caspase-1 pathway modulation with high confidence.

Evidence & Benchmarks

• VX-765 (A8238) reduces IL-1β and IL-18 secretion in LPS-primed macrophages without altering TNFα or IL-6 levels (Johnson et al., 2020).
• In collagen-induced arthritis mouse models, oral VX-765 significantly reduces joint inflammation and cytokine output at 50–100 mg/kg/day (APExBIO).
• In HIV-infected lymphoid tissue explants, VX-765 prevents dose-dependent CD4 T-cell pyroptosis (1–30 µM, pH 7.5, 24 h) (Johnson et al., 2020).
• VX-765 is insoluble in water but dissolves in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonic agitation), supporting diverse in vitro and in vivo experimental needs (APExBIO).
• Compared to non-selective caspase inhibitors, VX-765 does not suppress non-inflammasome cytokines, ensuring pathway specificity (see translational review—this article details new cross-species data).

Applications, Limits & Misconceptions

VX-765 is widely applied in preclinical studies of:

• Inflammatory and autoimmune disorders (e.g., arthritis, dermatitis).
• Pyroptosis in myeloid cells and lymphocytes.
• HIV-associated CD4 T-cell death.
• Epilepsy and neuropathic pain (investigational).

VX-765 supports mechanistic studies of the caspase signaling pathway, especially where precise inhibition of IL-1β and IL-18 maturation is required. It provides a more targeted approach than pan-caspase or broad-spectrum protease inhibitors, reducing interpretive ambiguity in cytokine studies (see prior benchmark—here, we emphasize cell-type selectivity and workflow controls).

Common Pitfalls or Misconceptions

• VX-765 is not effective in cell types lacking caspase-1 expression, such as many non-myeloid lineages (Johnson et al., 2020).
• It does not inhibit non-canonical inflammasome pathways (e.g., caspase-4/5/11-dependent pyroptosis).
• VX-765 does not suppress non-inflammasome cytokines (TNFα, IL-6, IL-8, IL-α); off-target anti-inflammatory effects are minimal at recommended doses.
• Solubility is limited in aqueous media; improper formulation may result in precipitation and variable dosing.
• Long-term storage of VX-765 solutions can lead to degradation; short-term use and desiccated storage at -20°C are advised (APExBIO).

Workflow Integration & Parameters

For in vitro assays, VX-765 is typically dissolved in DMSO and diluted into buffered media (pH 7.5) immediately prior to use. Additives such as 1 mM DTT and 2% BSA may be included to stabilize enzyme activity. Recommended working concentrations range from 1–50 µM, depending on cell type and endpoint. For in vivo studies, oral dosing at 50–100 mg/kg/day has demonstrated efficacy in mouse models. Solutions should be prepared fresh and used within 24 hours. Storage is desiccated at -20°C; light and moisture exposure are minimized. APExBIO provides the compound as a solid under SKU A8238, ensuring consistent lot-to-lot performance (see product page).

Compared to earlier reviews (see translational guidance—this article gives updated formulation and storage guidance), this article details the latest best practices for VX-765 integration in cell, tissue, and animal workflows.

Conclusion & Outlook

VX-765 is a validated, selective caspase-1 inhibitor supporting high-specificity research on IL-1β/IL-18 biology and pyroptosis. Its well-characterized pharmacology, robust preclinical data, and commercial availability from APExBIO make it a preferred tool for inflammation and immune signaling studies. Future directions include expanded investigation of its efficacy in human disease models and further clarification of its cell-type specificity. For comprehensive product details and ordering, see the VX-765 (A8238) product page.